Veronica Veschi, M.D., Ph.D.
My research interest is in the field of pediatric oncology, in particular a better understanding of the molecular mechanisms underlying neuroblastoma (NB) tumorigenesis. I am developing a high-throughput, high-content-focused epigenetic siRNA and chemical screen to identify epigenetic regulators of neuroblastoma growth and differentiation. The aim is to develop novel epigenetic therapies for high-risk NB patients.
My research interest is in the field of pediatric oncology, in particular in a better understanding of the molecular mechanisms underlying neuroblastoma (NB) tumorigenesis. My studies focused on the epigenetic alterations involved in NB pathogenesis. Given that many components of the epigenome are enzymes and potentially druggable, it is important to identify those that have the greatest impact on NB tumor cell growth and differentiation as they may provide novel additional therapeutic options. I performed a high-throughput, high-content-focused epigenetic siRNA and chemical screen in different NB cell lines. I am currently focusing on functional analysis of the candidates genes that came out as the most statistically significant genes combining siRNA and chemical screening results.
Selected Recent Publications
- Mol Cancer Res. 9(1): 67-77, 2011. [ Journal Article ]
- Mol Carcinog. 52(7): 526-34, 2013. [ Journal Article ]
Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.PLoS One. 7(11): e49139, 2012. [ Journal Article ]
Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma.Front Oncol. 2: 141, 2012. [ Journal Article ]
Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.Cell Death Dis. 5: e1100, 2014. [ Journal Article ]
I graduated in medicine and surgery in 2006 at Sapienza University of Rome, Italy. I manifested my deeper interest for a more basic approach in research and, while I was attending the M.D. specialty school in oncology, I also worked in a laboratory that was investigating the molecular mechanisms of protoncogenes such as HMGA1 and MYCN in the neuroblastoma tumor. After my specialization in oncology in 2011, I began working on my Ph.D in molecular medicine, splitting my research time between the laboratory of Dr. Giuseppe Giannini in Rome, Italy, and Dr. Carol J. Thiele's laboratory at the NCI. I joined NIH in February 2013 as an M.D. oncologist and Ph.D. student in Dr. Thiele's laboratory, the Cell and Molecular Biology Section of the Pediatric Oncology Branch at NCI and my actual position is postdoctoral visiting fellow in her laboratory. My area of study is developing a high-throughput, high-content-focused epigenetic siRNA and chemical screen to identify the epigenetic regulators of neuroblastoma growth and differentiation.